MTHFR isoform carriers. 5-MTHF (5-methyl tetrahydrofolate) vs folic acid: a key to pregnancy outcome: a case series

Abstract

Purpose

To evaluate the possibility of correcting metabolic defects in gametes and embryos due to methylene tetra hydrofolate reductase (MTHFR) isoforms C677T and A1298C, by supplementation with 5-methyl THF instead of synthetic folic acid. In these couples, high doses of folic acid lead to UMFA (un-metabolized folic acid) syndrome.

Methods

Thirty couples with fertility problems lasting for at least 4 years, such as recurrent fetal loss, premature ovarian insufficiency, or abnormal sperm parameters, with two thirds of them having failed assisted reproductive technology (ART) attempts were included in this program. For all couples, at least one of the partners was a carrier of one of the two main MTHFR isoforms. Most of the women had been previously treated unsuccessfully with high doses of folic acid (5 mg/day), according to what is currently proposed in the literature. The couples carrying one of the isoforms were treated for 4 months with 5-MTHF, at a dose of 600 micrograms per day, before attempting conception or starting another attempt at ART. The duration of treatment corresponding to an entire cycle of spermatogenesis is approximately 74 days.

Results

In this first series of 33 couples, one couple was not followed-up, and two are still currently under treatment. No adverse effects were observed. Thirteen of the couples conceived spontaneously, the rest needing ART treatment in order to achieve pregnancy. Only three couples have, so far, not succeeded.

Conclusion

The conventional use of large doses of folic acid (5 mg/day) has become obsolete. Regular doses of folic acid (100–200 μg) can be tolerated in the general population but should be abandoned in the presence of MTHFR mutations, as the biochemical/genetic background of the patient precludes a correct supply of 5-MTHF, the active compound. A physiological dose of 5-MTHF (800 μg) bypasses the MTHFR block and is suggested to be an effective treatment for these couples. Moreover, it avoids potential adverse effects of the UMFA syndrome, which is suspected of causing immune dysfunction and other adverse pathological effects such as cancer (especially colorectal and prostate).

This is a preview of subscription content, log in to check access.

Fig. 1

References

  1. 1.

    Menezo Y, Khatchadourian C, Gharib A, Hamidi J, Greenland T, Sarda N. Regulation of S-adenosyl methionine synthesis in the mouse embryo. Life Sci 1989;44:1601–9.

  2. 2.

    Silvestris E, Cohen M, Cornet D, Jacquesson-Fournols L, Clement P, Chouteau J, et al. Supporting the one-carbon cycle restores ovarian reserve in subfertile women: absence of correlation with urinary bisphenol A concentration. Biores Open Access. 2017;6:104–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  3. 3.

    Dattilo M, Cornet D, Amar E, Cohen M, Menezo Y. The importance of the one carbon cycle nutritional support in human male fertility: a preliminary clinical report. Reprod Biol Endocrinol. 2014;12:71.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. 4.

    Cornet D, Amar E, Cohen M, Ménézo Y. Clinical evidence for the importance of 1-carbon cycle support in subfertile couples. Austin J Reprod Med Infertil. 2015;2:1011.

    Google Scholar 

  5. 5.

    Cornet D, Cohen M, Clement A, Amar E, Fournols L, Clement P, et al. Association between the MTHFR-C677T isoform and structure of sperm DNA. J Assist Reprod Genet. 2017;34:1283–8.

    Article  PubMed  PubMed Central  Google Scholar 

  6. 6.

    National Center for Biotechnology Information (2016) Comparison of the effect of low-dose supplementation with L-5-methyltetrahydrofolate or folic acid on plasma homocysteine. U.S National Library of medicine.

  7. 7.

    Servy E, Menezo Y. The methylene tetrahydrofolate reductase (MTHFR) isoform challenge. High doses of folic acid are not a suitable option compared to 5 Methyltetrahydrofolate treatment. Clin Obstet Gynecol Reprod Med. 2017;3:1–5.

    Article  Google Scholar 

  8. 8.

    Botto LD, Yang Q. 5, 10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epidemiol. 2000;151:862–77.

    Article  PubMed  CAS  Google Scholar 

  9. 9.

    Gong M, Dong W, He T, Shi Z, Huang G, Ren R, et al. MTHFR 677CT polymorphism increases the male infertility risk: a meta-analysis involving 26 studies. PLoS One. 2015;10:e0121147.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. 10.

    Yang Y, Luo YY, Wu S, Tang YD, Rao XD, Xiong L, et al. Association between C677T and A1298C polymorphisms of the MTHFR gene and risk of male infertility: a meta-analysis. Genet Mol Res 2016; 15(2). https://doi.org/10.4238/gmr.15027631.

  11. 11.

    Tara SS, Ghaemimanesh F, Zarei S, Reihani-Sabet F, Pahlevanzadeh Z, Modarresi MH, et al. Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms in male partners of recurrent miscarriages couples. J Reprod Infertil. 2015;16:193–8.

    PubMed  PubMed Central  Google Scholar 

  12. 12.

    Enciso M, Sarasa J, Xanthopoulou L, Bristow S, Bowles M, Fragouli E, et al. Polymorphisms in the MTHFR gene influence embryo viability and the incidence of aneuploidy. Hum Genet. 2016;135:555–68.

    Article  PubMed  CAS  Google Scholar 

  13. 13.

    Ware WR. Raising concerns about unmetabolized folic acid. J Orthomol Med. 2008;23:43–51.

    Google Scholar 

  14. 14.

    Christensen KE, Mikael LG, Leung KY, Lévesque N, Deng L, Wu Q, et al. High folic acid consumption leads to pseudo-MTFHR deficiency, altered lipid metabolism, and liver injury in mice. Am J Clin Nutr. 2015;101:646–58.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. 15.

    Prinz-Langenohl R, Bramswig S, Tobolski O, Smulders YM, Smith DE, et al. 5-MTHF increases plasma folate more effectively than folic acid in women with the homozygous or wild-type6777C ->T polymorphism of MTHFR. Br J Pharmacol. 2009;158:2014–21.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. 16.

    Cornet D, Cohen M, Clement A, Amar E, Fournols L, Clement P, et al. Association between the MTHFR-C677T isoform and structure of sperm DNA. J Assist Reprod Genet. 2017;34:1283–8.

    Article  PubMed  PubMed Central  Google Scholar 

  17. 17.

    Brämswig S, Prinz-Langenohl R, Lamers Y, Tobolski O, Wintergerst E, Berthold HK, et al. Supplementation with a multivitamin containing 800 microg of folic acid shortens the time to reach the preventive red blood cell folate concentration in healthy women. Int J Vitam Nutr Res. 2009;79:61–70.

    Article  PubMed  CAS  Google Scholar 

  18. 18.

    Zappacosta B, Romano L, Pershichilli S, Cutrone LA, Graziano M, et al. Genotype prevalence and allele frequencies of 5,10-Methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms in Italian newborns. Lab Med. 2009;40:732–6.

    Article  Google Scholar 

  19. 19.

    Georgiades P, Watkins M, Burton GJ, Ferguson-Smith AC. Roles for genomic imprinting and the zygotic genome in placental development. Proc Natl Acad Sci U S A. 2001;98:4522–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  20. 20.

    Serman L, Dodig D. Impact of DNA methylation on trophoblast function. Clin Epigenetics. 2011;3:7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  21. 21.

    Koukoura O, Sifakis S, Spandidos DA. DNA methylation in the human placenta and fetal growth. Mol Med Rep. 2012;5:883–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  22. 22.

    Branco MR, King M, Perez-Garcia V, Bogutz AB, Caley M, Fineberg E, et al. Maternal DNA methylation regulates early trophoblast development. Dev Cell. 2016;36:152–63.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. 23.

    Lucock M, Yates Z. Folic acid fortification: a double-edged sword. Curr Opin Clin Nutr Metab Care. 2009;12:555–64.

    Article  PubMed  CAS  Google Scholar 

  24. 24.

    Bønaa KH, Njølstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. NORVIT Trial Investigators N Engl J Med. 2006;354:1578–88.

    Article  PubMed  Google Scholar 

  25. 25.

    Lucock M, Yates Z. Folic acid—vitamin and panacea or genetic time bomb? Nat Rev Genet. 2005;6:235–40.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Affiliations

Authors

Contributions

Edouard J Servy, MD, FACOG, followed clinically the patients and collected the data.

Laetitia Jacquesson-Fournols, MD, Endocrinologist,, followed clinically the patients and collected the data.

Marc Cohen MD, Obst Gyn, follows clinically the patients and collected the data.

Yves J R Menezo, PhD, Dr. Sci, FRSM, Senior Clinical Embryologist (ESHRE) (*corresponding author) controlled dosages designed the protocol and wrote the paper.

Corresponding author

Correspondence to Yves J. R. Menezo.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest except MC who is dealing with a company saling Neutraceuticals.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Servy, E.J., Jacquesson-Fournols, L., Cohen, M. et al. MTHFR isoform carriers. 5-MTHF (5-methyl tetrahydrofolate) vs folic acid: a key to pregnancy outcome: a case series. J Assist Reprod Genet 35, 1431–1435 (2018). https://doi.org/10.1007/s10815-018-1225-2

Download citation

Keywords

  • MTHFR
  • Gametes
  • Embryos
  • Miscarriages
  • Folic acid
  • 5-MTHF
  • UMFA